To the full analysis
Maravai LifeSciences Holdings stock: growth
MRVIMaravai LifeSciences Holdings reported $185.74M in revenue for fiscal 2025, down 28.3% on the prior year, down 8.1% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
6%
per year from 2018 to 2025, per share −1.2%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2018 | |
|---|---|---|
| Revenue | −8.1% | 6.0% |
| Revenue per share | −15.3% | −1.2% |
| Earnings | no data | no data |
| Earnings per share | no data | no data |
| Free cash flow | no data | no data |
| Free cash flow per share | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2018 | $123.83M | −$17.73M | −$3.8M |
| 2019 | $143.14M | −$8.49M | $6.97M |
| 2020 | $284.1M | $76.89M | $126.78M |
| 2021 | $799.24M | $182.04M | $353.72M |
| 2022 | $883M | $220.21M | $518.89M |
| 2023 | $288.95M | −$119.03M | $60.67M |
| 2024 | $259.19M | −$144.85M | −$22.19M |
| 2025 | $185.74M | −$130.77M | −$70.72M |
Revenue by region
Where Maravai LifeSciences Holdings, Inc. generates its revenue.
- North America61%
- Asia Pacific22%
- EMEA17%
Figures as a table
| 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|
| North America | $141.06M | $127.09M | $112.38M | 60.5% |
| Asia Pacific | $97.44M | $89.38M | $41.47M | 22.3% |
| EMEA | $49.92M | $42.06M | $30.92M | 16.6% |
| Total revenue | $288.95M | $259.19M | $185.74M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Sep 2024)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.